These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 25959702)

  • 1. Diversity of 1,213 hepatitis C virus NS3 protease sequences from a clinical virology laboratory database in Marseille university hospitals, southeastern France.
    Hajji H; Aherfi S; Motte A; Ravaux I; Mokhtari S; Ruiz JM; Poizot-Martin I; Tourres C; Tivoli N; Gérolami R; Tamalet C; Colson P
    J Med Virol; 2015 Nov; 87(11):1921-33. PubMed ID: 25959702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis C virus NS3 protease genotyping and drug concentration determination during triple therapy with telaprevir or boceprevir for chronic infection with genotype 1 viruses, southeastern France.
    Aherfi S; Solas C; Motte A; Moreau J; Borentain P; Mokhtari S; Botta-Fridlund D; Dhiver C; Portal I; Ruiz JM; Ravaux I; Bregigeon S; Poizot-Martin I; Stein A; Gérolami R; Brouqui P; Tamalet C; Colson P
    J Med Virol; 2014 Nov; 86(11):1868-76. PubMed ID: 25052594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NS3 protease of genotype 3 subtype h HCV identified in southeastern France.
    Colson P; Gayet S; Gerolami R
    Antivir Ther; 2011; 16(4):615-9. PubMed ID: 21685551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequence analysis of NS3 protease gene in clinical strains of hepatitis C virus.
    Lodrini S; Bagaglio S; Canducci F; De Mitri MS; Andreone P; Loggi E; Lazzarin A; Clementi M; Morsica G
    J Biol Regul Homeost Agents; 2003; 17(2):198-204. PubMed ID: 14518724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NS3 protease polymorphism and natural resistance to protease inhibitors in French patients infected with HCV genotypes 1-5.
    Vallet S; Viron F; Henquell C; Le Guillou-Guillemette H; Lagathu G; Abravanel F; Trimoulet P; Soussan P; Schvoerer E; Rosenberg A; Gouriou S; Colson P; Izopet J; Payan C;
    Antivir Ther; 2011; 16(7):1093-102. PubMed ID: 22024525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Naturally occurring hepatitis C virus (HCV) NS3/4A protease inhibitor resistance-related mutations in HCV genotype 1-infected subjects in Italy.
    Vicenti I; Rosi A; Saladini F; Meini G; Pippi F; Rossetti B; Sidella L; Di Giambenedetto S; Almi P; De Luca A; Caudai C; Zazzi M
    J Antimicrob Chemother; 2012 Apr; 67(4):984-7. PubMed ID: 22258932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genotyping and resistance profile of hepatitis C (HCV) genotypes 1-6 by sequencing the NS3 protease region using a single optimized sensitive method.
    Besse B; Coste-Burel M; Bourgeois N; Feray C; Imbert-Marcille BM; André-Garnier E
    J Virol Methods; 2012 Oct; 185(1):94-100. PubMed ID: 22728274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates.
    López-Labrador FX; Moya A; Gonzàlez-Candelas F
    Antivir Ther; 2008; 13(4):481-94. PubMed ID: 18672527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implications of baseline polymorphisms for potential resistance to NS3 protease inhibitors in Hepatitis C virus genotypes 1a, 2b and 3a.
    Palanisamy N; Danielsson A; Kokkula C; Yin H; Bondeson K; Wesslén L; Duberg AS; Lennerstrand J
    Antiviral Res; 2013 Jul; 99(1):12-7. PubMed ID: 23648709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Worldwide distribution of the NS3 gene 80K polymorphism among circulating hepatitis C genotype 1 viruses: implication for simeprevir usage.
    Vidal LL; Santos AF; Soares MA
    J Antimicrob Chemother; 2015 Jul; 70(7):2024-7. PubMed ID: 25835991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular characterization of hepatitis C virus for determination of subtypes and detection of resistance mutations to protease inhibitors in a group of intravenous drug users co-infected with HIV.
    Silva T; Cortes Martins H; Coutinho R; Leitão E; Silva R; Pádua E
    J Med Virol; 2015 Sep; 87(9):1549-57. PubMed ID: 25940586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels.
    Di Maio VC; Cento V; Di Paolo D; Aragri M; De Leonardis F; Tontodonati M; Micheli V; Bellocchi MC; Antonucci FP; Bertoli A; Lenci I; Milana M; Gianserra L; Melis M; Di Biagio A; Sarrecchia C; Sarmati L; Landonio S; Francioso S; Lambiase L; Nicolini LA; Marenco S; Nosotti L; Giannelli V; Siciliano M; Romagnoli D; Pellicelli A; Vecchiet J; Magni CF; Babudieri S; Mura MS; Taliani G; Mastroianni C; Vespasiani-Gentilucci U; Romano M; Morisco F; Gasbarrini A; Vullo V; Bruno S; Baiguera C; Pasquazzi C; Tisone G; Picciotto A; Andreoni M; Parruti G; Rizzardini G; Angelico M; Perno CF; Ceccherini-Silberstein F;
    J Antimicrob Chemother; 2016 Mar; 71(3):739-50. PubMed ID: 26679249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis C virus NS3/4A quasispecies diversity in acute hepatitis C infection in HIV-1 co-infected patients.
    Nevot M; Boesecke C; Parera M; Andrés C; Franco S; Revollo B; Ingiliz P; Tural C; Clotet B; Rockstroh JK; Martinez MA;
    J Viral Hepat; 2014 Jun; 21(6):e19-28. PubMed ID: 24674023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic heterogeneity of the NS3 protease gene in hepatitis C virus genotype 1 from untreated infected patients.
    Vallet S; Gouriou S; Nousbaum JB; Legrand-Quillien MC; Goudeau A; Picard B
    J Med Virol; 2005 Apr; 75(4):528-37. PubMed ID: 15714495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and Validation of Two Screening Assays for the Hepatitis C Virus NS3 Q80K Polymorphism Associated with Reduced Response to Combination Treatment Regimens Containing Simeprevir.
    Chui CK; Dong WW; Joy JB; Poon AF; Dong WY; Mo T; Woods CK; Beatty C; Hew H; Harrigan PR; Brumme CJ
    J Clin Microbiol; 2015 Sep; 53(9):2942-50. PubMed ID: 26135875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance mutations are rare among protease inhibitor treatment-naive hepatitis C genotype-1 patients with or without HIV coinfection.
    Lisboa-Neto G; Noble CF; Pinho JR; Malta FM; Gomes-Gouvêa MS; Alvarado-Mora MV; da Silva MH; Leite AG; Piccoli LZ; Rodrigues FK; Carrilho FJ; Mendes-Correa MC
    Antivir Ther; 2015; 20(3):281-7. PubMed ID: 25279715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of the NS3 Q80K polymorphism by Sanger and deep sequencing in hepatitis C virus genotype 1a strains in the UK.
    Beloukas A; King S; Childs K; Papadimitropoulos A; Hopkins M; Atkins M; Agarwal K; Nelson M; Geretti AM
    Clin Microbiol Infect; 2015 Nov; 21(11):1033-9. PubMed ID: 26232533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conservation of hepatitis C virus nonstructural protein 3 amino acid sequence in viral isolates during liver transplantation.
    Mello IM; Thumann C; Schvoerer E; Soulier E; Pinho JR; Silvestre DA; Queiroz AT; Wolf P; Baumert TF; Keller FS; Pereira CA
    J Viral Hepat; 2009 Oct; 16(10):732-7. PubMed ID: 19486468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Investigation of Drug Resistance Substitutions in NS3 Protease Sequence of Hepatitis C Virus from Non-Responder Patients.
    Nejabat N; Hosseini SY; Sarvari J; Gorzin AA; Fattahi MR; Rasoolian M
    Asian Pac J Cancer Prev; 2019 Aug; 20(8):2311-2317. PubMed ID: 31450900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HCV genotype 1-6 NS3 residue 80 substitutions impact protease inhibitor activity and promote viral escape.
    Pham LV; Jensen SB; Fahnøe U; Pedersen MS; Tang Q; Ghanem L; Ramirez S; Humes D; Serre SBN; Schønning K; Bukh J; Gottwein JM
    J Hepatol; 2019 Mar; 70(3):388-397. PubMed ID: 30395912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.